A per-patient compassionate program of PLX-PAD for treatment of COVID-19 coronavirus patients
Latest Information Update: 03 Apr 2023
At a glance
- Drugs Emiplacel (Primary)
- Indications COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- Sponsors Pluri
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 09 Oct 2020 New trial record